Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Pressemeddelelse

Stayble Therapeutics: BioStock: Stayble is done with the 6-month follow-up

Stayble Therapeutics

At the beginning of the week, the pharmaceutical company Stayble Therapeutics achieved an important milestone in the phase IIb study with STA363 when 100 patients had completed their 6-month visit. This means that Stayble has secured all the necessary data required to evaluate the study's primary endpoint - to show pain reduction in patients with chronic disc-related back pain. Stayble is now one step closer to presenting top-line data, which is expected to take place during the fourth quarter of 2023.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/02/stayble-is-done-with-the-6-month-follow-up/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.